Cynosure Inc (CYNO) 10-K Annual Report February 2016


Timothy Baker				Scott Solomon
President, Chief Operating Officer				Senior Vice President
and Chief Financial Officer				Sharon Merrill Associates
Cynosure, Inc.				(617) 542-5300
(978) 256-4200				CYNO@investorrelations.com
tbaker@cynosure.com

Cynosure Announces Fourth-Quarter 2015 Results;

Achieves Record Quarterly Revenue of $102.4 Million, 19 Percent

Increase from Prior Year

Fourth-Quarter 2015 Highlights:

–	North America product revenue of $55.8 million, up 31 percent year-over-year

–	Non-GAAP earnings of $0.42 per diluted share; GAAP earnings of $0.31 per diluted share

–	Launch of SculpSure^® platform for non-invasive fat reduction helps drive top-line performance

–	Cash and investments of $182.8 million at December 31, 2015

Full-Year 2015 Highlights:

–	Revenue of $339.5 million, up 16 percent year-over-year

–	Non-GAAP earnings of $1.08 per diluted share; GAAP earnings of $0.70 per diluted share

–	Cash flow from operations of $37.8 million

Westford, MA – February 9, 2016

– Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months and year ended December 31, 2015.

“We capped a record year with fourth-quarter revenue of $102.4 million, improving margins and solid profitability in the quarter,” said Chief Executive Officer Michael Davin. “The successful launch of SculpSure, our new laser platform for non-invasive fat reduction, together with the strong performance of other products, including MonaLisa Touch^®, Icon™ and PicoSure^®, helped drive a 31 percent increase in product revenue from North America and enhance our competitive position in the market.”

“2015 was an outstanding year for Cynosure. We launched a second wavelength to our market-leading PicoSure platform and introduced SculpSure in the U.S. through our direct sales force as

The following information was filed by Cynosure Inc (CYNO) on Tuesday, February 9, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/885306/000119312516485689/d107402d10k.htm

View differences made from one year to another to evaluate Cynosure Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Cynosure Inc.

Continue

Assess how Cynosure Inc's management team is paid from their Annual Proxy

Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Cynosure Inc provided additional information to their SEC Filing as exhibits

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: CYNO
CIK: 885306
Form Type: 10-K Annual Report
Accession Number: 0001193125-16-485689
Submitted to the SEC: Mon Feb 29 2016 5:25:22 PM EST
Accepted by the SEC: Mon Feb 29 2016
Period: Thursday, December 31, 2015
Industry: Electromedical And Electrotherapeutic Apparatus